Nimbus Therapeutics

Primary contact

Nimbus Therapeutics is a biotechnology company that has developed a computational chemistry platform, enabled through its privileged partnership with co-founder Schrödinger, to design treatments for substantial and underserved human diseases. The company's focus on metabolic diseases, cancer and immune-inflammatory disorders reflects the mechanistic relationship between these disorders, and Nimbus' ability to rapidly tackle well validated targets as well as those that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry, resulting in medicines with high potency, selectivity and other desirable drug-like properties. At its core, Nimbus is a drug discovery company.
Primary contact

Funding 💰

Total $72M
Select investors Atlas Venture, Lilly Ventures, SR One, Pfizer Ventures, Lightstone Ventures, Bill Gates
Last update: May 8, 2018